{"id":"W4392805481","doi":"10.1007/s10637-024-01428-0","title":"A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Université Laval","funders":"","keywords":"Selumetinib; Medicine; Pembrolizumab; Adverse effect; Internal medicine; MEK inhibitor; Gastroenterology; Pharmacology; Urology; Oncology; Cancer; Colorectal cancer; MAPK/ERK pathway; Immunotherapy; Chemistry; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001245433,0.001519028,0.001511633,0.0003947268,0.0003378702,0.0006720037,0.0005487355,0.0009478317,0.002536543],"category_scores_gemma":[0.000579935,0.0005326612,0.0009047488,0.0002620024,0.0005698761,0.0005665643,0.0002810104,0.002574194,0.000612947],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005887681,"about_ca_system_score_gemma":0.0009728437,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006359657,"about_ca_topic_score_gemma":0.001660013,"domain_scores_codex":[0.9996964,0.0001537638,0.0000120695,0.00005372075,0.00002934693,0.00005477303],"domain_scores_gemma":[0.9996737,0.00005374505,0.00006249905,0.00001827595,0.0000218512,0.0001699688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6547149,0.08463463,0.005651883,0.001516527,0.001797144,0.0006398732,0.0004511668,0.004152615,0.09980886,0.0005765681,0.007701109,0.1383548],"study_design_scores_gemma":[0.5030928,0.4787663,0.007326986,0.00004526775,0.000392613,0.0003581358,0.00004328864,0.001784083,0.004803751,0.0002286558,0.003132736,0.00002535244],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919999,0.002421227,0.0005175482,0.0004564802,0.0001297659,0.001972877,0.0006723551,0.00007030254,0.001759585],"genre_scores_gemma":[0.9872875,0.002467064,0.002099345,0.0008764178,0.0001708765,0.002270021,0.002049023,0.00002523463,0.002754459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002536543,"threshold_uncertainty_score":0.008485556,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02116369759197948,"score_gpt":0.2994471895682759,"score_spread":0.2782834919762964,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}